Incyte (INCY) Stock Overview
A biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 6/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
INCY Community Fair Values
Create NarrativeSee what 66 others think this stock is worth. Follow their fair value or set your own to get alerts.
Incyte Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$84.61 |
| 52 Week High | US$87.24 |
| 52 Week Low | US$53.56 |
| Beta | 0.72 |
| 1 Month Change | 11.93% |
| 3 Month Change | 25.50% |
| 1 Year Change | 27.60% |
| 3 Year Change | 22.43% |
| 5 Year Change | -5.71% |
| Change since IPO | 4,412.53% |
Recent News & Updates
Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Aug 14
Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings
Aug 06Recent updates
Incyte Corporation's (NASDAQ:INCY) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Aug 14Additional Considerations Required While Assessing Incyte's (NASDAQ:INCY) Strong Earnings
Aug 06Incyte: New CEO Brings A New Possible Outcome
Jul 03Investors Aren't Buying Incyte Corporation's (NASDAQ:INCY) Revenues
Apr 30Incyte: Still A 'Buy' Despite HS Treatment Data With Povorcitinib
Mar 18Incyte: Q4 Earnings Outlines Multiple Drug Launches In 2025
Feb 11Incyte: Multiple Drug Launches Bode Well For Future Growth
Jan 11Incyte: Q3 Earnings Ramping Up Growth To Jump The Patent Cliff
Oct 31
Tactical Expansions And First-in-Class Molecules Set To Propel Growth In High-Need Medical Areas
Incyte's focus on expanding its clinical pipeline with first-in-class molecules and novel therapies aims to drive growth by increasing market share and revenue.Incyte: Monjuvi Advancement Continues With Positive FL Treatment Data
Aug 19Incyte: The Worst Has Been Avoided
Jun 16Incyte Pharmaceuticals: Cheap Enough Now (Rating Upgrade)
Apr 26Incyte: A Potential GARP Superstar
Feb 27Shareholder Returns
| INCY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.7% | 0.2% | 0.4% |
| 1Y | 27.6% | -9.9% | 15.7% |
Return vs Industry: INCY exceeded the US Biotechs industry which returned -9.9% over the past year.
Return vs Market: INCY exceeded the US Market which returned 15.7% over the past year.
Price Volatility
| INCY volatility | |
|---|---|
| INCY Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 17.2% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: INCY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INCY's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1991 | 2,617 | Bill Meury | www.incyte.com |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive.
Incyte Corporation Fundamentals Summary
| INCY fundamental statistics | |
|---|---|
| Market cap | US$16.52b |
| Earnings (TTM) | US$870.87m |
| Revenue (TTM) | US$4.58b |
Is INCY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INCY income statement (TTM) | |
|---|---|
| Revenue | US$4.58b |
| Cost of Revenue | US$2.14b |
| Gross Profit | US$2.44b |
| Other Expenses | US$1.57b |
| Earnings | US$870.87m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.46 |
| Gross Margin | 53.22% |
| Net Profit Margin | 18.99% |
| Debt/Equity Ratio | 0% |
How did INCY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/02 09:41 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Incyte Corporation is covered by 57 analysts. 21 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jasper Hellweg | Argus Research Company |
| Thomas Russo | Baird |
| Ishan Majumdar | Baptista Research |